Firefly Neuroscience (NASDAQ:AIFF) Raised to Hold at Wall Street Zen

Firefly Neuroscience (NASDAQ:AIFF) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Firefly Neuroscience Stock Performance

AIFF stock opened at $1.76 on Friday. Firefly Neuroscience has a one year low of $0.62 and a one year high of $4.51. The stock has a market capitalization of $26.03 million, a PE ratio of -0.98 and a beta of 0.58. The company has a fifty day moving average of $1.52 and a 200-day moving average of $1.58.

Firefly Neuroscience (NASDAQ:AIFF) last released its earnings results on Tuesday, March 31st. The company reported ($0.16) EPS for the quarter. Firefly Neuroscience had a negative return on equity of 229.99% and a negative net margin of 1,740.98%.The firm had revenue of $0.41 million during the quarter.

Institutional Trading of Firefly Neuroscience

Several hedge funds have recently made changes to their positions in AIFF. Jane Street Group LLC acquired a new stake in shares of Firefly Neuroscience in the 4th quarter worth $53,000. Savvy Advisors Inc. acquired a new stake in shares of Firefly Neuroscience in the third quarter valued at about $63,000. Geode Capital Management LLC lifted its stake in shares of Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after purchasing an additional 58,067 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Firefly Neuroscience by 393.3% in the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after purchasing an additional 401,085 shares during the period. Institutional investors and hedge funds own 4.96% of the company’s stock.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.